Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.62
-0.08
(-2.96%)
USD |
NASDAQ |
Oct 30, 16:00
2.64
+0.02
(+0.76%)
After-Hours: 20:00
Bridgebio Oncology Therapeutics Enterprise Value : -13.30M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | -13.30M |
| October 29, 2026 | -6.886M |
| October 28, 2026 | 1.125M |
| October 27, 2026 | -7.688M |
| October 26, 2026 | -11.69M |
| October 23, 2026 | -10.09M |
| October 22, 2026 | 5.131M |
| October 21, 2026 | -8.489M |
| October 20, 2026 | -5.284M |
| October 19, 2026 | 5.131M |
| October 16, 2026 | 2.727M |
| October 15, 2026 | 13.14M |
| October 14, 2026 | 9.537M |
| October 13, 2026 | 13.14M |
| October 12, 2026 | 37.98M |
| October 09, 2026 | 41.98M |
| October 08, 2026 | 50.80M |
| October 07, 2026 | 52.40M |
| October 06, 2026 | 57.21M |
| October 05, 2026 | 65.22M |
| October 02, 2026 | 88.45M |
| October 01, 2026 | 92.46M |
| September 30, 2026 | 105.27M |
| September 29, 2026 | 90.85M |
| September 28, 2026 | 82.04M |
| Date | Value |
|---|---|
| September 25, 2026 | 93.26M |
| September 24, 2026 | 96.46M |
| September 23, 2026 | 110.08M |
| September 22, 2026 | 150.14M |
| September 21, 2026 | 150.14M |
| September 18, 2026 | 158.95M |
| September 17, 2026 | 168.57M |
| September 16, 2026 | 158.15M |
| September 15, 2026 | 167.76M |
| September 14, 2026 | 181.38M |
| September 11, 2026 | 173.37M |
| September 10, 2026 | 219.04M |
| September 09, 2026 | 317.98M |
| September 08, 2026 | 486.62M |
| September 04, 2026 | 496.24M |
| September 03, 2026 | 489.83M |
| September 02, 2026 | 489.03M |
| September 01, 2026 | 483.42M |
| August 31, 2026 | 481.82M |
| August 28, 2026 | 477.01M |
| August 27, 2026 | 512.26M |
| August 26, 2026 | 518.67M |
| August 25, 2026 | 527.48M |
| August 24, 2026 | 509.05M |
| August 21, 2026 | 504.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Korsana Biosciences, Inc. | 16.93M |
| IRulya Therapeutics, Inc. | 61.34M |
| PepGen Inc. | 62.31M |
| Q32 Bio, Inc. | 110.52M |
| Arrowhead Pharmaceuticals, Inc. | 8.229B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.45M |
| Total Expenses (Quarterly) | 56.45M |
| EPS Diluted (Quarterly) | -705.20 |
| Earnings Yield | -47.05K% |
| Normalized Earnings Yield | -47054.49 |